Lightchain Capital

Recent News

wugen-logo-400
May 20, 2024

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

READ MORE
Logo-Geneoscopy-400
May 14, 2024

Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solution

READ MORE
C4-logo-wht
May 08, 2024

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

READ MORE
Logo-Geneoscopy-400
May 06, 2024

FDA Approves ColoSense™ - Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

READ MORE
C4-logo-wht
April 29, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
C4-logo-wht
April 09, 2024

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

READ MORE
C4-logo-wht
April 08, 2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

READ MORE
Logo-Geneoscopy-400
April 03, 2024

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

READ MORE
wugen-logo-400
March 14, 2024

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group